Cargando…

Neutrophil activation identifies patients with active polyarticular gout

BACKGROUND: Gout is the most prevalent inflammatory arthritis in developed countries. A gout flare is mediated by phagocytosis of monosodium urate crystals by macrophages and neutrophils leading to subsequent activation of neutrophils contributing to synovitis, local joint destruction, and systemic...

Descripción completa

Detalles Bibliográficos
Autores principales: Vedder, D., Gerritsen, M., Duvvuri, B., van Vollenhoven, R. F., Nurmohamed, M. T., Lood, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304179/
https://www.ncbi.nlm.nih.gov/pubmed/32552822
http://dx.doi.org/10.1186/s13075-020-02244-6
_version_ 1783548214192898048
author Vedder, D.
Gerritsen, M.
Duvvuri, B.
van Vollenhoven, R. F.
Nurmohamed, M. T.
Lood, C.
author_facet Vedder, D.
Gerritsen, M.
Duvvuri, B.
van Vollenhoven, R. F.
Nurmohamed, M. T.
Lood, C.
author_sort Vedder, D.
collection PubMed
description BACKGROUND: Gout is the most prevalent inflammatory arthritis in developed countries. A gout flare is mediated by phagocytosis of monosodium urate crystals by macrophages and neutrophils leading to subsequent activation of neutrophils contributing to synovitis, local joint destruction, and systemic inflammation. We hypothesize that biomarkers from activated neutrophils reflect gout disease activity. The objective of this study therefore was to investigate the clinical utility of neutrophil-derived biomarkers in gout disease activity. METHODS: Plasma samples from 75 gout patients participating in the “Reade gout cohort Amsterdam” were compared with 30 healthy controls (HC). Levels of neutrophil extracellular traps (NETs) and neutrophil activation markers (calprotectin and peroxidase activity) were analyzed by ELISA and fluorimetry, compared to healthy controls, and related to markers of inflammation and disease activity. RESULTS: Levels of NETs, as well as neutrophil activation markers, were increased in gout patients compared to HC (p < 0.01). No associations were found between markers of cell death (cell-free DNA and NETs) and disease activity. Cell-free levels of genomic DNA were elevated among gout patients compared to HC (p < 0.05) and related to the number of gout attacks in the last year (β = 0.35, p < 0.01). Peroxidase activity correlated with disease activity (RAPID score: β = 0.49, p < 0.01, MHAQ: β = 0.66, p < 0.01) and inflammation markers (CRP: β = 0.25, p = 0.04, and ESR: β = 0.57, p < 0.001). Involvement of ankle or wrist resulted in significant higher peroxidase levels compared to mono-articular disease (β = 0.34, p < 0.01), indicating that peroxidase activity is a marker of poly-articular gout. Calprotectin (S100A8/A9) correlated with the inflammation marker CRP (β = 0.23, p = 0.05) and morning stiffness, especially in patients with chronic poly-articular gout (β = 0.71, p < 0.01). CONCLUSIONS: Neutrophil activation markers are associated with characteristics of active, polyarticular gout. Furthermore, NETs are present in the peripheral blood of gout patients. However, NETs do not associate with markers of disease activity or inflammation. Future research should point out if peroxidase and calprotectin could be used in clinical practice as biomarkers for monitoring gout disease activity.
format Online
Article
Text
id pubmed-7304179
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-73041792020-06-22 Neutrophil activation identifies patients with active polyarticular gout Vedder, D. Gerritsen, M. Duvvuri, B. van Vollenhoven, R. F. Nurmohamed, M. T. Lood, C. Arthritis Res Ther Research Article BACKGROUND: Gout is the most prevalent inflammatory arthritis in developed countries. A gout flare is mediated by phagocytosis of monosodium urate crystals by macrophages and neutrophils leading to subsequent activation of neutrophils contributing to synovitis, local joint destruction, and systemic inflammation. We hypothesize that biomarkers from activated neutrophils reflect gout disease activity. The objective of this study therefore was to investigate the clinical utility of neutrophil-derived biomarkers in gout disease activity. METHODS: Plasma samples from 75 gout patients participating in the “Reade gout cohort Amsterdam” were compared with 30 healthy controls (HC). Levels of neutrophil extracellular traps (NETs) and neutrophil activation markers (calprotectin and peroxidase activity) were analyzed by ELISA and fluorimetry, compared to healthy controls, and related to markers of inflammation and disease activity. RESULTS: Levels of NETs, as well as neutrophil activation markers, were increased in gout patients compared to HC (p < 0.01). No associations were found between markers of cell death (cell-free DNA and NETs) and disease activity. Cell-free levels of genomic DNA were elevated among gout patients compared to HC (p < 0.05) and related to the number of gout attacks in the last year (β = 0.35, p < 0.01). Peroxidase activity correlated with disease activity (RAPID score: β = 0.49, p < 0.01, MHAQ: β = 0.66, p < 0.01) and inflammation markers (CRP: β = 0.25, p = 0.04, and ESR: β = 0.57, p < 0.001). Involvement of ankle or wrist resulted in significant higher peroxidase levels compared to mono-articular disease (β = 0.34, p < 0.01), indicating that peroxidase activity is a marker of poly-articular gout. Calprotectin (S100A8/A9) correlated with the inflammation marker CRP (β = 0.23, p = 0.05) and morning stiffness, especially in patients with chronic poly-articular gout (β = 0.71, p < 0.01). CONCLUSIONS: Neutrophil activation markers are associated with characteristics of active, polyarticular gout. Furthermore, NETs are present in the peripheral blood of gout patients. However, NETs do not associate with markers of disease activity or inflammation. Future research should point out if peroxidase and calprotectin could be used in clinical practice as biomarkers for monitoring gout disease activity. BioMed Central 2020-06-18 2020 /pmc/articles/PMC7304179/ /pubmed/32552822 http://dx.doi.org/10.1186/s13075-020-02244-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Vedder, D.
Gerritsen, M.
Duvvuri, B.
van Vollenhoven, R. F.
Nurmohamed, M. T.
Lood, C.
Neutrophil activation identifies patients with active polyarticular gout
title Neutrophil activation identifies patients with active polyarticular gout
title_full Neutrophil activation identifies patients with active polyarticular gout
title_fullStr Neutrophil activation identifies patients with active polyarticular gout
title_full_unstemmed Neutrophil activation identifies patients with active polyarticular gout
title_short Neutrophil activation identifies patients with active polyarticular gout
title_sort neutrophil activation identifies patients with active polyarticular gout
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7304179/
https://www.ncbi.nlm.nih.gov/pubmed/32552822
http://dx.doi.org/10.1186/s13075-020-02244-6
work_keys_str_mv AT vedderd neutrophilactivationidentifiespatientswithactivepolyarticulargout
AT gerritsenm neutrophilactivationidentifiespatientswithactivepolyarticulargout
AT duvvurib neutrophilactivationidentifiespatientswithactivepolyarticulargout
AT vanvollenhovenrf neutrophilactivationidentifiespatientswithactivepolyarticulargout
AT nurmohamedmt neutrophilactivationidentifiespatientswithactivepolyarticulargout
AT loodc neutrophilactivationidentifiespatientswithactivepolyarticulargout